AJMC - Change is Coming

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 22, 2024

Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

Author(s)Robert O'Brien, RPh, Diana I. Brixner, PhD, RPh, Ashley Peterson, MHA

Medical experts identify key stakeholders within health plans who collaborate in the decision-making process for coverage, access, and benefit design related to prescription digital therapeutics.

Episodes in this series

Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"

EP. 1 Differentiating PDTs from Wellness Apps and Evaluating Efficacy

Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"

EP. 2 Payer Needs and Strategies for Evaluating and Covering PDTs

A panel of 4 experts on PDTs

EP. 3 Payers Review Process and Effective Strategies for PDT Coverage

A panel of 4 experts on PDTs

EP. 4 Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

Video 5 - "Dawn of the Age of Adopting PDTs"

EP. 5 Dawn of the Age of Adopting PDTs

Video 6 -"Identifying the Most Impactful Disease Areas and Patient Populations for PDTs"

EP. 6 Identifying the Most Impactful Disease Areas and Patient Populations for PDTs

4 KOLs discuss PDTs

EP. 7 Evolving Commercialization and Distribution Models for PDTs

4 KOLs discuss PDTs

EP. 8 Promoting Appropriate PDT Prescribing Through Provider Education and Support

A panel of 4 experts on PDTs

EP. 9 Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs

A panel of 4 experts on PDTs

EP. 10 Optimizing Benefit Design and Implementation for Improved PDT Access

A panel of 4 experts on PDTs

EP. 11 PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Shaping the Future of Community Bispecific Administration: Lessons From ASH 2025

ByTara Graff, DO

January 29th 2026

Sequencing, Real-World Evidence, and Unmet Needs: Key Immunotherapy Insights From ASH 2025 in Multiple Myeloma

ByKrina Patel, MD, MSc

January 29th 2026

The Promise of In Vivo CAR T: Expanding Access Through Off-the-Shelf Innovation

ByKrina Patel, MD, MSc

January 29th 2026

Optimizing Adverse Event Management for Bispecific Antibodies in the Community

ByTara Graff, DO

January 29th 2026

Child cancer Image credit Alexis Scholtz:peopleimages.com.jpeg

Advances in Pediatric Dermatology Spotlight Diagnostic Precision and New Systemics

ByGiuliana Grossi

January 28th 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Trending on AJMC

Trulicity, Botox Headline Drugs Included in the Third Cycle of Medicare Price Negotiations

CLL Breakthrough: 100% Efficacy Reported for VenR Retreatment

AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule

New Dermatologic Therapies Make Waves at Maui Derm 2026

Optimizing Nonsurgical Management of Skin Tumors at Maui Derm 2026

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.